KIFC1 and cancer: Furthermore, we developed a potential centrosome abnormality biomarker applicable to routinely fixed paraffin-embedded tumor tissue to enable patient segmentation of those with cancers susceptible to KIFC1/centrosome amplification targeted therapy.